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e.2013.03Abstract Introduction: Hepatitis C virus (HCV) is a major public health problem and a leading
cause of chronic liver disease. An estimated 180 million people are infected worldwide. The preva-
lence of hepatitis C virus (HCV) infection is relatively low in children, with an anti-HCV prevalence
rate of 0.2–0.4% in the Western world. Egypt has the highest prevalence of adult HCV infection in
the world, averaging 15–25% in rural communities. The main (90%) HCV genotype is type 4. The
magnitude of HCV infection in children is not well studied. Asymptomatic HCV infection is detect-
able in 2.02% of Egyptian children.
Aim: To study the clinical presentation and histopathological features of the liver in children with
chronic hepatitis C infection.
Methods: The study population included 40 children from 2 to 16 years who had been diagnosed
with chronic hepatitis C (HCV-RNA positive for 6 months or more by Real-time PCR) in the liver
clinic at El-Shatby Children Hospital.NA, ribo nucleic acid; ALT,
– trans ferase; GGT, gamma
rnational normalization ratio.
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364 M.M. Abd-Elgawad et al.Results: Among the 40 patients’ biopsies, 26 (65%) were stage 0, 10 (25%) were stage 1, 4 (10%)
were stage 2–3 (HAI). The grades of all 40 children ranged between 0 and 1 (HAI). Developing
ﬁbrosis was signiﬁcantly associated with age (P= 0.015).
Conclusion: Children with chronicHCV infection are generally asymptomatic. Signiﬁcant hepatic ﬁbro-
sis was present in 10%of children withHCV infection. Fibrosis stage was signiﬁcantly higher in older age
children. There was no signiﬁcant association between ﬁbrosis stage and any biochemical parameter.
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The hepatitis C virus (HCV) is a major public health problem
and a leading cause of chronic liver disease.1 An estimated
180 million people are infected worldwide.1 Egypt has the
highest prevalence of adult HCV infection in the world, aver-
aging 15–25% in rural communities.2
The magnitude of HCV infection in children is not well stud-
ied. Asymptomatic HCV infection is detectable in 2.02% of
Egyptian children.3 In two-community based cross sectional
studies, the ﬁrst study from Upper Egypt, 84 (3%) out of 2967
subjects under 19 years of age screened for HCV antibody using
the ELISA technique, were found to be positive.4 In the second
study fromLower Egypt, 178 (9%) out of the 2010 screened sub-
jects under 19 years of age were found to be positive.5
The main (90%) HCV genotype is type 4.6
Although blood transfusion, vertical transmission, and liv-
ing in a housewith an infected familymember are the established
risk factors for HCV transmission, approximately 70% of ac-
quired infections are due to unidentiﬁed risk factors.7,8 The clin-
ical presentation of HCV; the incubation period ranges from 6
to 12 weeks. Acute infection usually occurs without any signs
or symptoms. Few patients (<30%) will experience fever, mal-
aise, nausea, abdominal discomfort and jaundice. HCV RNA
can be detected within 2 weeks, and alanine amino transferase
(ALT) will increase about 1 month after infection.
Chronic infection is usually asymptomatic, but can be asso-
ciated with fatigue especially in teens and adults. Patients who
present with anorexia, weight loss, abdominal pain, hepatomeg-
aly, and splenomegaly usually have advanced liver disease.9
Both adult and pediatric patients lack stigmata of chronic
liver disease until they develop signs of decompensated liver
disease. Some physical examination ﬁndings may include asci-
tes, edema, jaundice, palmar erythema, spider nevi, caput me-
dusa, gynecomastia, hypogonadism, hepatosplenomegaly,
leuconychia, cyanosis, clubbing, fetor hepaticus, enlarged par-
otid gland, paraumbilical hernia, abdominal bruits, scant body
hair, and other clues (e.g., excoriations, petechia, and tattoos).
Patients with HCV can also demonstrate extrahepatic manifes-
tations of infection, such as cryoglobulinemia, porphyria cuta-
nea tarda, or necrotizing vasculitis.10 Hepatitis C virus (HCV)
progresses gradually, and can result in serious complications
such as cirrhosis and hepatocellular carcinoma.11 However,
data on the natural history and histopathology of HCV-related
liver disease in children are conﬂicting.12–16 Studies from Japan
and Europe point to a relatively benign clinical and histopath-
ologic liver disease17–20 whereas studies from the USA suggest
a more aggressive course with development of early ﬁbrosis.21–
25 Geographic variation in genotypes and diversity of the
infected population studied may account for some of these dif-
ferences, in addition to, as yet unknown viral/host factors.26–28The lack of uniformity in the descriptions of the natural his-
tory, clinical presentation and histologic features of HCV
infection in children prompted us to evaluate 40 HCV infected
children followed in our liver unit.
1.1. Subjects
The current study was a prospective study carried out at Al-
Shatby Hospital. The study population included 40 children
aged from 2 to 16 years who had been diagnosed with chronic
HCV infection; i.e.: having HCV-RNA positive for 6 months
or more by Real-time PCR which is a molecular assay method
for HCV RNA detection and quantiﬁcation with detection
limit = 12 IU/ml.29 None of these patients was under treat-
ment during the study.
1.2. Inclusion criteria
Children will be eligible for the study if they have:
 Positive anti-HCV antibody. (Axsym system HCV version
3.0 Abbott Diagnostic Division: Germany).30
 Positive HCV RNA in serum for 6 months or more.29
 Compensated liver disease (total serum bilirubin 61.5 mg/
dL; INR 61.5; serum albuminP3.4, d Acceptable hemato-
logical and biochemical indices (Hemoglobin P12 g/dL;
neutrophil count P1500/cmm, platelet count P75,000/
cmm and serum creatinine 61.5 mg/dl).1.3. Exclusion criteria
 Evidence of hepatic decompensation (hepatic encephalopa-
thy or ascites).
 Other liver diseases, such as hepatitis B or schistosomiasis.
2. Methods
Informed consent was obtained from the child´s parents and
ethical approval of the study protocol was secured from the
Ethics Committee of Alexandria Faculty of Medicine.
All children were subjected to:
1. Thorough history taking
2. Full clinical examination; stressing on abdominal examina-
tion for assessment of liver span and consistency, splenic
size and signs of liver disease.
3. Routine laboratory investigations including: urine analysis,
complete blood picture, kidney function tests and liver
function tests.
4. Abdominal ultrasound.
5. Percutaneous liver biopsy using a Menghini 14 mm or
16 mm gauge needle was performed in all children.
Table 2 Distribution of the chronic HCV children according
to the presence of symptoms.
HCV symptoms Test of signiﬁcance
No. % z p
Symptomatic 1 0.4 0.57 0.569
Asymptomatic 39 97.5
Total 40 100
Table 3 Distribution of the chronic HCV children according
to some biochemical data.
Some biochemical data HCV children
ALT Rang 37–42
Mean ± SD 39 ± 1.2
AST IU/L Rang 18–51
Mean ± SD 35 ± 9.9
Albumin gm% Rang 2–4.1
Mean ± SD 3 ± 1.1
INR Rang 1–1.9
Mean ± SD 0.3 ± 1.6
GGT mg/dl Rang 23–35
Mean ± SD 30 ± 3.3
Table 4 Distribution of the chronic HCV children according
to the degree of ﬁbrosis in their liver biopsies.
Degree of ﬁbrosis HCV cases
No. %
No Fibrosis 26 65
Mild ﬁbrosis 10 25
Moderate ﬁbrosis 2 5
Severe ﬁbrosis 2 5
No ﬁbrosis: HAI score 0.
Mild ﬁbrosis: HAI score 1.
Moderate ﬁbrosis: HAI score 2–3.
Severe ﬁbrosis: HAI score 4–6.
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and grade of liver injury.31
All biopsy specimens were ﬁxed in formalin and parafﬁn
embedded. Four-um thick sections stained with hematoxylin-
eosin and Masson trichrome were available for examination
in all cases.
3. Results
Table 1 shows that 15% of chronic HCV children were below
5 years, 35% were from 5 to below 10 years and 50% were
from 10 to 15 years old, and 71.2% of chronic HCV children
were males while 28.8% were female.
Table 2 shows that only one case in the studied group had
fatigue as a symptom of chronic HCV infection.
Table 3 shows that all cases had ALT serum levels within
normal values (ULN= 65 IU/L)34 and their mean was
39 ± 1.2. Also AST had normal value (ULN= 35 IU/L)32
with a mean of 35 ± 9.9. Regarding GGT serum level, it
was within normal range with a mean of 30 ± 3.3 mg/dl. Liver
synthetic functions were impaired in four cases, where they had
low serum albumin level (2 gm%)34 and prolonged INR (1.6-
1.9).32
Table 4 shows that among 40 patients’ liver biopsies; 26
(65%) had no ﬁbrosis, while only 5% showed severe ﬁbrosis.
All biopsies showed a mild degree of inﬂammation according
to Ishak classiﬁcation schemes31 and two biopsies showed
steatosis.
Table 5 shows a signiﬁcant correlation between the degree
of ﬁbrosis in liver biopsies and the age of chronic HCV
children.
Although there was an increase in the ALT level with an in-
crease in the degree of ﬁbrosis; this was not statistically signif-
icant. This is true for all other biochemical tests (Table 6).
4. Discussion
In Egypt and other developing countries, high rates of HCV
infection are observed in all age groups, suggesting that an
ongoing risk of HCV acquisition still exists. Egypt has one
of the highest prevalence rates of HCV infection worldwide,Table 1 Distribution of the chronic HCV children according
to their demographic data.
Cases (n= 40) Test of signiﬁcance
No. % t p-Value
Age (mean ± SD) 9.2 ± 3.4 0.62 0.536
Age groups No. % X2 p-Value
<5 6 15 0.355 0.837
10 14 35
16 20 50
Gender
Male 27 71.2 0.318 0.573
Female 13 28.8
Residence
Rural 28 81.8 1.553 0.213
Urban 12 18.2averaging 12–24% in the general population. HCV genotype
4 is the most prevalent genotype in Egypt (90%).3
The prevalence of HCV infection is relatively low in chil-
dren, with an anti-HCV prevalence rate of 0.2–0.4% in the
Western world.1 Few studies have evaluated the epidemiology
and risk factors of HCV infection in children in Egypt. A study
reported that HCV seroprevalence among Egyptian children
ranges from 0.5% to 3%.6 Age range in the present study
was 2–16 years. This very young age of HCV cases was also re-
ported by Wendy et al.33 who reported an age range from
3 months.33 Khalil et al.34 in Assiut University Hospital re-
ported 465 cases of HCV infection with an age range of
2 months to 15 years.34 The early onset of HCV infection in
the present study and other reports is explained by vertical
transmission from pregnant infected mothers who are not
screened for HCV and the role of transmission (use of contam-
inated tools during labor whether at hospitals or at home). In
addition routine screening of all mothers is not yet mandatory.
Current screening guidance suggests checking hepatitis C anti-
bodies only in pregnant women with high risk factors of a
Table 5 Correlation between the age of the chronic HCV children and degree of ﬁbrosis in their liver biopsies.
Degree of ﬁbrosis Age (years) Test of signiﬁcance
<5 5–10 10–16 Total t p-Value
No ﬁbrosis 5 12 9 26 1.318 0.005*
Mild ﬁbrosis 1 1 8 10 1.210 0.340
Moderate ﬁbrosis 0 1 1 2 1.113 0.156
Severe ﬁbrosis 0 0 2 2 1.120 0.022*
Total 6 14 20 40 1.553 0.213
No ﬁbrosis: HAI score 0.
Mild ﬁbrosis: HAI score 1.
Moderate ﬁbrosis: HAI score 2–3.
Severe ﬁbrosis: HAI score 4–6.
* signiﬁcant if p> 0.05
Table 6 Correlation between some biochemical tests of chronic HCV children and degree of ﬁbrosis in their liver biopsies.
Biochemical tests Degree of ﬁbrosis Test of signiﬁcance
No ﬁbrosis Mild ﬁbrosis Moderate ﬁbrosis Severe ﬁbrosis t p-Value
ALT Mean ± SD 28 ± 3 34 ± 2 37 ± 5 40 ± 2 1.327 0.432
AST Mean ± SD 18 ± 7 33 ± 4 48 ± 3 51 ± 3 1.312 0.342
GGT Mean ± SD 23 ± 4 28 ± 3 32 ± 5 35 ± 9 1.142 0.256
Albumin Mean ± SD 4.1 ± 1.2 3.8 ± 1.1 3.5 ± 1.3 2 ± 1.1 1.430 0.341
INR Mean ± SD 1 ± 0.2 1.2 ± 0.3 1.3 ± 0.3 1.9 ± 0.3 1.443 0.114
No ﬁbrosis: HAI score 0.
Mild ﬁbrosis: HAI score 1.
Moderate ﬁbrosis: HAI score 2–3.
Severe ﬁbrosis: HAI score 4–6.
366 M.M. Abd-Elgawad et al.current or past history of IV drug abuse, women who received
clotting factor concentrates produced before 1987, or a blood
transfusion or an organ transplant before 1992, women who
were on chronic hemodialysis, women with persistent abnor-
mal liver function tests and health care workers after needle
sticks or mucosal exposure to HCV positive as well as infants
of infected mothers. These categories of high risk patients
should be tested for anti-HCV at 1 year and followed up for
the development of hepatitis.35 Chronic HCV infection is asso-
ciated with numerous clinical manifestations. In our study,
only one case had symptoms in the form of fatigue in agree-
ment with El-Raziky et al. study.3
The use of liver biopsy to assess the degree of ﬁbrosis in
children with chronic hepatitis C infection has been discussed
in many aspects; whether is is mandatory or not or the exis-
tence of other alternatives for this invasive procedure. Other
queries also are as yet unanswered; should it be an initial step
in deciding whether to start treatment or should we keep the
candidate under strict follow up. In our practice, liver biopsy
is still the gold standard in assessing ﬁbrosis of HCV cases
and for deciding the management plan. Delgado-Borrego
et al.36 stated that children with HCV should undergo liver
biopsy to determine the presence and degree of ﬁbrosis. In
the absence of ﬁbrosis, treatment may be deferred. If any de-
gree of hepatic ﬁbrosis is present, antiviral therapy for HCV
should be considered.36
In our study a total 40 cases with chronic hepatitis C infec-
tion underwent liver biopsy. There was no signiﬁcant correla-
tion between the degree of ﬁbrosis in liver biopsies and the
gender of chronic HCV children.A signiﬁcant correlation between the degree of ﬁbrosis in li-
ver biopsies and the age of chronic HCV children was detected
where 10% of our cases had a signiﬁcant degree of ﬁbrosis at
the age of 10–16 years. Kamran et al.37 reported that portal
ﬁbrosis was present in 78% of the specimens, including ﬁbrous
portal expansion (26%), bridging ﬁbrosis (22%), bridging
ﬁbrosis with architectural distortion (22%), and cirrhosis
(8%). Centrilobular pericellular ﬁbrosis, has not been previ-
ously reported in the context of chronic hepatitis C infection
in adults or children.37 Goodman et al. added that, the positive
correlation of inﬂammation with duration of infection and
ﬁbrosis, and of obesity with ﬁbrosis suggests that children with
chronic hepatitis C will be at risk for progressive liver disease
as they age and possibly acquire other comorbid risk factors.38
Jara et al.39 considered liver biopsy as the accurate tool for
assessment of lesions produced by chronic hepatitis. Although
not performed in every affected child, it usually reveals mild le-
sions. They also stated that the use of non-invasive biochemi-
cal tests (Fibro-Test and Acti-Test) is being evaluated in
children with hepatitis C for their correlation with histology.39
Chen et al.40 also conﬁrmed that the liver biopsy is the gold
standard for the grading and staging of chronic hepatitis C.
The grade is variable in chronic HCV infection.40 In the vast
majority of pediatric treatment trials of hepatitis C, patients
were candidate for treatment only if liver histology was avail-
able. This point of view augments our policy in treating these
children. So to prove that it is not mandatory to perform a li-
ver biopsy, Iorio et al.41 performed liver biopsy in 67 children
with chronic hepatitis C infection before they started any treat-
ment and it was repeated again after 5.5 years. Only one child
Chronic hepatitis C in children: Clinical spectrum and histopathological study 367had micronodular cirrhosis. This ﬁnding conﬁrms the idea that
histological assessment cannot affect the management plan
and that chronic hepatitis C in children seems to be a milder
disease with a more favorable natural course when compared
to hepatitis C virus (HCV) infection in adults.41
El-Hawary et al.41 conducted a study at Fayoum University
to assess hepatic ﬁbrosis in children with chronic hepatitis C
infection. They agreed that a liver biopsy provides good data.
It conﬁrms the diagnosis and excludes other liver diseases, as
well as accurately assessing both grade and stage of the
disease.42
5. Conclusion
Children with chronic HCV infection are generally asymptom-
atic. Signiﬁcant hepatic ﬁbrosis was present in 10% of children
with HCV infection. Fibrosis stage was insigniﬁcantly higher
in older age children. There was no signiﬁcant association be-
tween ﬁbrosis stage and any biochemical parameter.
Recommendation: 1-HCV is a global health problem. Pa-
tients and doctors should be aware about this virus and the
ways by which it can be transmitted. 2-Patients and doctors
should be aware of the nature of HCV liver disease, patients
should be well educated about their disease and the importance
of following up regularly. 3-Liver biopsy although it is the
most important diagnostic tool used to assess the degree of
inﬂammations and stage of ﬁbrosis in children with chronic
hepatitis C virus infection; it carries the hazards of being an
invasive procedure. Searching for reliable non invasive tech-
niques became mandatory for better management of cases.
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